Laverock Therapeutics Raises £13.5M

Summation

  • The funding will enable further development of the GEiGS technology and progression of Laverock's programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumor responsive T-cell and macrophage-based immune therapies, through to in vitro and in vivo validation.
  • We're pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted responsive treatments.
  • “We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies.

Sciad Newswire / Laverock Therapeutics, established in 2021 to commercialize the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M. This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund, and Tekfen Ventures.

The funding will enable further development of the GEiGS technology and progression of Laverock’s programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumor responsive T-cell and macrophage-based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.

David Venables, CEO of Laverock, commented: “GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted responsive treatments.”

Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies. We backed David’s previous venture, Synpromics, which delivered an exceptional return for Calculus investors in 2019. Laverock’s ambitious plans hold tremendous potential for the healthcare sector, and we are excited to be part of the journey.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Funding will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations reports Phenomix Sciences.

R3 Vascular Announces $87 Million in Series B Financing

R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. 

Nami Surgical Secures Investment to Transform Robotic-Assisted Surgery Market

Nami Surgical develops miniaturised ultrasonic medical devices for surgical applications, and supports medical device companies to deliver innovation in ultrasonic surgery. In a groundbreaking development, Nami has introduced a high-performance, miniaturised ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery. Traditionally favoured in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.

By using this website you agree to accept Medical Device News Magazine Privacy Policy